Mutant Prion Protein Expression Causes Motor and Memory Deficits and Abnormal Sleep Patterns in a Transgenic Mouse Model  by Dossena, Sara et al.
Neuron
ArticleMutant Prion Protein Expression Causes Motor and
Memory Deficits and Abnormal Sleep Patterns
in a Transgenic Mouse Model
Sara Dossena,1,2,8 Luca Imeri,4,8 Michela Mangieri,5 Anna Garofoli,1,2 Loris Ferrari,1,4 Assunta Senatore,1,2
Elena Restelli,1,2 Claudia Balducci,2 Fabio Fiordaliso,3 Monica Salio,3 Susanna Bianchi,4 Luana Fioriti,1,2,9
Michela Morbin,5 Alessandro Pincherle,6 Gabriella Marcon,5,7 Flavio Villani,6 Mirjana Carli,2 Fabrizio Tagliavini,5
Gianluigi Forloni,2 and Roberto Chiesa1,2,*
1Dulbecco Telethon Institute, 20156 Milan, Italy
2Department of Neuroscience
3Bio-imaging Unit, Department of Cardiovascular Research
‘‘Mario Negri’’ Institute for Pharmacological Research, 20156 Milan, Italy
4Department of Human Physiology, University of Milan Medical School, 20133 Milan, Italy
5Division of Neuropathology and Neurology
6Division of Clinical Epileptology and Experimental Neurophysiology
‘‘Carlo Besta’’ National Neurological Institute, 20133 Milan, Italy
7Department of Pathology and Experimental Medicine, University of Udine, 33100 Udine, Italy
8These authors contributed equally to this work
9Present address: Department of Neuroscience, Columbia University, New York, NY 10032, USA
*Correspondence: chiesa@marionegri.it
DOI 10.1016/j.neuron.2008.09.008SUMMARY
A familial form of Creutzfeldt-Jakob disease (CJD) is
linked to theD178N/V129prionprotein (PrP)mutation.
Tg(CJD) mice expressing the mouse homolog of this
mutant PrP synthesize amisfolded form of themutant
protein, which is aggregated and protease resistant.
Thesemice develop clinical and pathological features
reminiscent of CJD, including motor dysfunction,
memory impairment, cerebral PrP deposition, and
gliosis. Tg(CJD) mice also display electroencephalo-
graphic abnormalities and severe alterations of
sleep-wake patterns strikingly similar to those seen
in a humanpatient carrying theD178N/V129mutation.
Neurons in thesemice show swelling of the endoplas-
mic reticulum (ER) with intracellular retention of
mutant PrP, suggesting that ER dysfunction could
contribute to the pathology. These results establish
a transgenic animal model of a genetic prion disease
recapitulating cognitive, motor, and neurophysiologi-
cal abnormalities of the human disorder. Tg(CJD)
mice have the potential for giving greater insight
into the spectrum of neuronal dysfunction in prion
diseases.
INTRODUCTION
Clinical signs in the diagnosis of prion diseases in animal models
are essentially confined to late motor deficits. In humans, prion
diseases have a more complex presentation, with dementia
and nonmotor as well as motor disturbances, often following598 Neuron 60, 598–609, November 26, 2008 ª2008 Elsevier Inc.a long prodromal phase. A broader spectrum of clinical signs
is needed in experimental models for insight into the mecha-
nisms of neuronal dysfunction and its evolution, and to identify
earlier markers of clinical disease when therapeutic intervention
may be effective. Here we report the emergence of behavioral,
electrophysiological, and motor deficits in a mouse model of
inherited prion disease that closely mirror those seen in a newly
diagnosed human patient with the same mutation.
Approximately 15% of human prion diseases display autoso-
mal dominant inheritance and are linked to point or insertional
mutations in the gene encoding PrPC (PRNP) (Young et al.,
1999). The mechanism of neurotoxicity of mutant PrP molecules
is not clear (Chiesa and Harris, 2001), but structural changes in-
volving increased b sheet structure, aggregation, and resistance
to protease digestion may contribute to the pathogenicity of the
mutant protein (Prusiner, 1998). PRNP mutations have been
associated with defined clinical and neuropathological pheno-
types—Creutzfeldt-Jakob disease (CJD), Gerstmann-Stra¨uss-
ler-Scheinker syndrome (GSS), and fatal familial insomnia
(FFI)—but there is extensive variability in disease presentation
for individual mutations and even within the same family (Young
et al., 1999).
An important source of phenotypic variation is the polymor-
phism at codon 129 of PRNP, where either methionine (M) or va-
line (V) can be encoded. The prion disease linked to the substitu-
tion of aspartic acid (D) to asparagine (N) at codon 178 is a typical
example. The D178N/V129 haplotype segregates with a subtype
of Creutzfeldt-Jakob disease (CJD178) recognized clinically by
global cortical dementia, motor abnormalities, and myoclonus,
whereas the D178N/M129 allele is associated with FFI, primarily
characterized by severe sleep alterations, with total disorganiza-
tion of normal sleep structure and endocrine dysfunction (Gold-
farb et al., 1992). Electroencephalographic (EEG) changes
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Mouse Model of Inherited Creutzfeldt-Jakob Diseasecharacterize CJD (Wieser et al., 2006). However, sleep alter-
ations are also increasingly recognized in sporadic and inherited
CJD (Calleja et al., 1985; Chapman et al., 1996; Kazukawa et al.,
1987; Landolt et al., 2006; Taratuto et al., 2002; Terzano et al.,
1995).
Investigation of inherited prion disease biology requires animal
models with the essential features of the human disorders. To
date, the existing mouse models of inherited human prion dis-
ease, Tg(P101L) (Hsiao et al., 1990; Nazor et al., 2005; Telling
et al., 1996) and Tg(PG14) (Chiesa et al., 1998), develop motor
deficits, but models showing the cognitive and neurophysiolog-
ical abnormalities typical of CJD have not been reported.
Here we describe a transgenic mouse model of inherited CJD
expressing the mouse homolog of the D178N/V129 mutation, in
which we found EEG and sleep abnormalities as well as memory
impairment and motor dysfunction. Striking morphological alter-
ations of the neuronal endoplasmic reticulum (ER) associated
with ER retention of mutant PrP were found in these animals,
suggesting that perturbation of ER homeostasis may be involved
in the pathogenesis. These mice increase the spectrum of clini-
cal signs and other functional abnormalities in experimental
models of prion disease. They provide a platform for greater in-
sight into mechanisms of disease pathogenesis and for potential
approaches to intervention.
RESULTS
Generation of Transgenic Mice and Characterization
of Mutant PrP
We produced transgenic mice that express a mouse PrP
(moPrP) homolog of the D178N/V129 mutation associated with
CJD178 (moPrP D177N/V128). We identified five founders (A21,
G1, G5, H, and I). Transgene copy number and mutant PrP ex-
pression are shown in Table S1 and Figure S1 in the Supplemen-
tal Data available online. To generate transgenic lines, referred to
as Tg(CJD), founders were bred with Prnp0/0 mice (Bueler et al.,
1992), so that the progeny expressed only mutant PrP. The pat-
tern of transgenic PrP expression in the brain was similar to that
of endogenous PrP in nontransgenic mice (Figure S2), although
subtle differences in cellular distribution cannot be excluded.
Unglycosylated PrP was underrepresented (Figures S1 and
S2A), consistent with observations in humans carrying the
D178N mutation (Petersen et al., 1996).
Approximately 50% of mutant PrP in the mouse brains was in-
soluble (seen in pellet fractions in Figures 1A and 1B and
Figure S3) and was immunoprecipitated by the PrPSc-specific
antibody 15B3, which also recognizes a variety of misfolded
and aggregated forms of PrP (Biasini et al., 2008; Nazor et al.,
2005) (Figure 1B). No detergent-insoluble PrP was detected in
nontransgenic mice (Figure 1A, lanes 1 and 2).
Mutant PrP was weakly protease resistant (Figure 1C, lanes 5–
12), in contrast to the complete protease sensitivity of wild-type
PrP (Figure 1C, lanes 1–4). This was clearly seen under standard
assay conditions in the Tg(CJD-G5) founder expressing high
levels of mutant PrP. To enhance detection of the proteinase K
(PK)-resistant fraction in Tg(CJD-A21) mice, brain homogenates
were digested at 4C (Figure 1D). After deglycosylation with
PNGase F, the PK-resistant fragment found in Tg(CJD) micehad an apparent molecular mass of 19 kDa (Figure 1E). There
were no regional differences in insolubility and protease resis-
tance of mutant PrP throughout the brain (Figure S3 and data
not shown).
Figure 1. D177N/V128 PrP is Insoluble, Immunoprecipitated by 15B3
Antibody, and Mildly Protease Resistant
(A) Brain lysates prepared from mice of the following genotypes and ages were
ultracentrifuged at 186,0003 g for 40 min, and PrP in the supernatants (S) and
pellets (P) was analyzed by western blotting using P45–66 (lanes 1 and 2) or
3F4 antibody (lanes 3–10): non-Tg/Prnp+/+, 304 days (lanes 1 and 2); Tg(WT-
E1+/+), 581 days (lanes 3 and 4); Tg(CJD-A21+/), 570 days (lanes 5 and 6);
Tg(CJD-G1+/+), 309 days (lanes 7 and 8); Tg(CJD-G5+/)/Prnp+/+, 72 days
(lanes 9 and 10).
(B) Brain lysates from Tg(CJD-A21+/), 720 days (lanes 1 and 2) and Tg(WT-
E1+/+), 581 days (lanes 3 and 4) were ultracentrifuged, and the supernatant
and pellet fractions were split into two parts and either analyzed by western
blotting using antibody 3F4 (top panel) or immunoprecipitated using monoclo-
nal antibody 15B3 (lower panel). Immunoprecipitated PrP was analyzed by
western blotting using antibody 3F4 (lower panel).
(C) Brain lysates from mice of the following genotypes and ages were incu-
bated with 0–2 mg of proteinase K (PK) for 30 min at 37C, and PrP was
visualized by western blotting using antibody 3F4: Tg(WT-E1+/+), 42 days
(lanes 1–4); Tg(CJD-A21+/), 153 days (lanes 5–8); Tg(CJD-G5+/)/Prnp+/+,
72 days (lanes 9–12). The undigested samples (0 mg/ml PK) represent 50 mg
of protein; the other samples represent 200 mg.
(D) Brain lysates from a 71-day-old Tg(WT-E1+/) mouse and a 191-day-old
Tg(CJD-A21+/) mouse were incubated with 0–100 mg of PK for 60 min on
ice, and PrP was visualized by western blotting with antibody 3F4. The undi-
gested samples (0 mg/ml PK) represent 5 mg of protein; the other samples
represent 20 mg.
(E) Brain lysate from a 422-day-old Tg(CJD-A21+/) mouse was incubated with
0 or 75 mg/ml of PK as in (D), followed by incubation with PNGase F and west-
ern blot analysis with antibody 3F4. Deglycosylation of the undigested sample
in lane 1 was incomplete; arrowhead indicates the completely deglycosylated
PrP band.Neuron 60, 598–609, November 26, 2008 ª2008 Elsevier Inc. 599
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Mouse Model of Inherited Creutzfeldt-Jakob DiseaseTg(CJD) Mice DevelopMotor Dysfunction and Alteration
of Spatial Working Memory
All Tg(CJD) mice expressing mutant PrP at a level similar to that
of endogenous PrP in wild-type mice, or higher, exhibited
progressive neurological disease. They developed ataxia, with
abnormal posture, leaning to one side, unusual flexed posture
of hind legs, kyphosis, and foot clasping on suspension (Fig-
ure 2A). On a rotarod, Tg(CJD) mice showed a significantly
shorter latency to fall thanPrnp+/+ orPrnp0/0 nontransgenic litter-
mates and Tg(WT) mice (Figure S4).
The phenotype was evident from 450 days in hemizygous
Tg(CJD-A21) mice and145 days in homozygous mice. Duration
of illness was 293 ± 28 and 130 ± 13 days (Figure 2B), respec-
tively, suggesting a transgene dose-related neurological dys-
function. Furthermore, the Tg(CJD-G5) founder, which ex-
pressed mutant PrP at eight times wild-type levels, died with
neurological symptoms at 72 days of age, whereas mice express-
ing mutant PrP below the endogenous level did not develop neu-
rological disease during their lifetimes. Nontransgenic littermates
and Tg(WT) mice observed over the same period remained free of
neurological disease and survived more than 1000 days.
Coexpression of wild-type PrP had no effect on onset, sever-
ity, or duration of illness in Tg(CJD) mice, in contrast to the effect
of endogenous PrP expression in other transgenic mutant PrP
models (Telling et al., 1996). For example, in a group of litter-
Figure 2. Neurological Symptoms in Tg(CJD) Mice
(Aa) A Tg(CJD-A21+/+) mouse at 201 days of age is incapable of deambulating
on a metal grill.
(Ab) Two Tg(CJD-A21+/+) mice at 201 and 223 days of age. Note the ataxic
posture with extension of the hindlimb and the unbalanced posture.
(Ac) A Tg(CJD-A21+/) mouse at 671 days of age shows kyphosis (hunchback
position) and abnormal gait with extension of the hindlimbs.
(Ad) When suspended by its tail, a Tg(CJD-A21+/+) mouse at 188 days of
age (left) assumes a flexed posture and tightly clasps its hindlimbs, whereas
a nontransgenic littermate (right) splays its limbs.
(B) Time course of clinical illness in Tg(CJD-A21) mice.600 Neuron 60, 598–609, November 26, 2008 ª2008 Elsevier Inc.mates consisting of 10 Tg(CJD-A21+/)/Prnp+/+, 13 Tg(CJD-
A21+/)/Prnp+/0, and 7 Tg(CJD-A21+/)/Prnp0/0 mice, symptom
onset was at 405 ± 44, 409 ± 35, and 410 ± 39 days, respectively
(mean ± SEM).
We also found alterations in spatial working memory in
Tg(CJD) mice. Mice were tested with a battery of behavioral
tasks for different aspects of memory, including passive avoid-
ance, novel object recognition, Morris water maze, and eight-
arm radial maze. To avoid confounding effects due to the motor
deficit that develops in older mice, we tested Tg(CJD) hemizy-
gous animals younger than 320 days. Mice performed poorly in
the eight-arm radial maze, which tests spatial working memory,
making significantly more errors over 10 training days than non-
transgenic controls (Figure 3A). Latency to complete the test was
similar in Tg(CJD) and control mice, confirming that the deficit
was not due to motor abnormalities (Figure 3B). We found no
significant differences between Tg(CJD) and control mice in
the other behavioral tasks at this stage.
Tg(CJD) Mice Show Abnormal EEG Patterns and Sleep
Disturbance Reminiscent of Those Observed
in a Human CJD Patient with the Same Mutation
As EEG abnormalities are common in CJD (Wieser et al., 2006),
we analyzed EEG patterns in Tg(CJD) mice. The EEG activity of
Tg(CJD) mice was characterized by bursts of polyphasic com-
plexes (Figure 4A, left panels), which were not seen in the other
groups of mice. The polyphasic complexes lasted from 0.3 to
4.6 s, and their amplitude varied but in most cases was larger
than the EEG amplitude during non-REM (NREM) sleep. The
frequency power spectrum of polyphasic complexes peaked
Figure 3. Tg(CJD) Mice Show Working Memory Impairment in the
Eight-Arm Radial Maze
(A) Histograms show the mean ± SEM of total errors in the eight-arm radial
maze during 10 days of training by 10 non-Tg/Prnp+/+, 10 non-Tg/Prnp0/0,
and 11 Tg(CJD-A21+/) mice aged between 200 and 316 days. F2,28 = 9.0;
p = 0.001 by one-way analysis of variance (ANOVA). *p < 0.05, **p < 0.01 by
Tukey’s post hoc test.
(B) Values show the mean latency (±SEM) to complete the test. One-way
ANOVA did not find any difference between groups (F2,28 = 2.8; p = 0.08).
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Mouse Model of Inherited Creutzfeldt-Jakob DiseaseFigure 4. Electroencephalographic Activity
Is Altered in Tg(CJD) Mice
(A) Three examples of bursts of polyphasic com-
plexes (left panels) and corresponding frequency
power spectra obtained by fast Fourier transform
(right panels). These alterations were observed in
all 6 Tg(CJD-A21+/) mice.
(B) An example of sawtooth waves (left panel) and
the corresponding frequency power spectrum
(right panel), which were observed in 5 out of 6
Tg(CJD-A21+/) mice.
(C) Examples of normal electroencephalographic
recordings (left panels) and corresponding fre-
quency power spectra (right panel) during epochs
of wakefulness (top panel), non-rapid eye move-
ment (NREM) (middle panel), and rapid eye move-
ment (REM) (bottom panel) sleep in a representa-
tive Tg(WT) mouse.around 7–8 Hz (Figure 4A, right panels). Scoring epochs (12 s)
containing one or more bursts of polyphasic complexes were
almost equally distributed during the light and dark phases
(33.0% ± 5.5% and 27.8% ± 5.6% of the total number of epochs,
respectively). During the light phase, polyphasic complexes
were present in 36.1% ± 4.8%, 18.7% ± 4.0%, and 13.8% ±
7.4% of epochs scored as wakefulness, NREM sleep, and
REM sleep, respectively. These percentages were 29.7% ±
4.4%, 29.3% ± 2.9%, and 13.6% ± 11.3% during the dark
phase. As shown in the lower panel of Figure 5B, the polyphasic
complexes were distributed in clusters.
In 5 out of 6 Tg(CJD) mice, we also observed abnormal ‘‘saw-
tooth’’ waves with a frequency power spectrum that peaked
around 4 Hz (Figure 4B). The number of epochs with these waves
ranged from 5 to 33 during the light phase and from 4 to 56 during
the dark phase, except in one Tg(CJD) mouse in which hundreds
of sawtooth waves were recorded during the light-dark cycle.
Mice expressing mutant PrP showed marked sleep abnormal-
ities; 24 hr polygraphic analysis indicated significant alterations
of sleep-wake patterns. Tg(CJD) mice spent strikingly less time
in REM sleep than all other mouse lines during both phases of
the light-dark cycle (Figure 5A; top panel of Figure 5B; Figure 5E;
Figure S5). The amount of time spent in NREM sleep during the
dark phase was also significantly reduced. In Tg(CJD) mice,
3.9% ± 2.1% of time during the light phase and 4.7% ± 1.9%
during the dark phase was characterized by repeated bursts of
polyphasic complexes and could not be assigned to any conven-
tional behavioral state; these periods were classified as ‘‘un-
scored’’ (Figure 5B, top panel). There were no significant differ-
ences in the number of transitions between behavioral states
(an indicator of continuous or broken sleep) or state-specific
EEG power spectra in the different groups of mice.
Analysis of circadian distribution of sleep and gross body
movements did not bring to light any differences between
Tg(CJD) and control mice. As expected in nocturnal animals,
mice of all experimental groups spent more time awake (Fig-
ure 5E, top panel) and moved more during the dark phase than
the light phase of the light-dark cycle, with no differences be-tween strains (F3 = 0.64, p = 0.6 by two-way ANOVA). Animals
of all strains also slept more (as evaluated by total sleep time)
during the light phase than the dark phase. Thus, the extreme
reduction of REM sleep in Tg(CJD) mice could not be attributed
to alterations of circadian rhythms.
Our findings of marked EEG and sleep disruption in Tg(CJD)
mice expressing the mouse homolog of the D178N/V129mutation
confirm that sleep dysfunction is more widespread in prion dis-
eases than previously thought, consistent with recent reports of
such disturbances not only in FFI (Landolt et al., 2006). We there-
fore examined the sleep profile and EEG of a case of CJD178 in
a 47-year-old woman newly diagnosed during the course of our
experiments (see case report in the Supplemental Data).
We found EEG alterations (periodic sharp wave complex
[PSWC] activity) and marked abnormalities in the patient’s sleep
profile. NREM sleep EEG pattern was characterized by mono-
morphic low-amplitude theta and unstable delta activities, with
total absence of vertex waves, spindles, and K complex. Tripha-
sic waves were clearly attenuated during NREM sleep. REM
sleep, limited to brief phases during the night, appeared charac-
terized by very low-amplitude theta and beta rhythms, reduction
of submental electromyographic tone, and only rare rapid eye
movements (Figure S6). These severe EEG alterations meant
that the sleep-wake profile could not be scored according to
Rechtschaffen and Kales (1968). However, we identified three
patterns on the basis of the above characteristics: wake,
NREM sleep, and REM sleep (Figure 5D). Sleep appeared very
unstable, with frequent transitions between wakefulness and
NREM sleep. NREM sleep was also broken by frequent arousals
associated with limb movements (limb movement index = 64).
The respiratory profile was unremarkable.
In summary, some of the neurophysiological features of
Tg(CJD) mice are similar to those observed in the CJD178 patient.
Tg(CJD) Mice Show PrP Deposits, Gliosis,
and Loss of GABAergic Cells
Tg(CJD) mice exhibited several neuropathological abnormali-
ties. Immunohistochemistry indicated protease-resistant PrPNeuron 60, 598–609, November 26, 2008 ª2008 Elsevier Inc. 601
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Mouse Model of Inherited Creutzfeldt-Jakob DiseaseFigure 5. Abnormal Sleep Patterns in Tg(CJD) Mice and a Human CJD178 Patient
(A) Representative hypnogram of a 578-day-old Tg(WT-E1+/+) mouse. ‘‘Unscored’’ indicates epochs not assigned to any behavioral state. (See Results and
Experimental Procedures for further details.)
(B) Representative hypnogram (upper panel) and distribution across time of polyphasic complexes (lower panel) in a 631-day-old Tg(CJD-A21+/) mouse. Note
the reduction in REM sleep epochs (highlighted in red) in comparison to the Tg(WT-E1+/+) mouse and the presence of unscored epochs. Hypnograms in (A) and (B)
cover the first 6 hr of the light phase of the light-dark cycle and are intended to provide a qualitative picture of the amount of sleep and sleep distribution in time
(sleep architecture) during this interval.
(C) The 24 hr hypnogram of a healthy human shows a normal pattern of waking during the daytime and regular NREM-REM cycles during the night.
(D) Only a rudimentary wake-sleep rhythm is detectable in a human patient carrying the D178N/V129 PrP mutation, with a prevalence of waking during the day and
sleep epochs during the night. Note the absence of ultradian cycles, the severe reduction of REM sleep, and the impossibility to distinguish NREM sleep stages.
(E) Percentage of time (mean ± SEM) spent in wakefulness, NREM sleep, and REM sleep across 24 hr by 6 non-Tg/Prnp+/+, 6 non-Tg/Prnp0/0, 6 Tg(CJD-A21+/),
and 5 Tg(WT-E1+/+) mice. At the time of recording, the animals’ mean (±SEM) ages were: non-Tg/Prnp+/+, 629 ± 20 days; non-Tg/Prnp0/0, 632 ± 59 days; Tg(WT-
E1+/+), 427 ± 70 days; Tg(CJD-A21+/), 560 ± 34 days. The gray background identifies the dark portion of the light-dark cycle. Two-way ANOVA indicated
a significant reduction in the percentage of time spent in REM sleep during both the light and dark phases for the Tg(CJD) animals (F3,42 = 4.8, p = 0.01).
*p < 0.05, ***p < 0.001 versus other groups by Fisher’s test.deposits in many brain regions of Tg(CJD) mice that were absent
in nontransgenic and Tg(WT) mice (Figures 6A–6D). Diffuse ‘‘syn-
aptic-type’’ PrP deposition was prominent in the hippocampal
formation, particularly in the stratum moleculare (Figure 6E),
and in the amygdala and olfactory bulb. Definite PrP immunos-
taining was also detected in the neocortex and striatum and,
less intensely, in the thalamus, hypothalamus, brainstem, and
molecular layer of the cerebellum. In addition, small PrP ‘‘pla-
que-like’’ deposits were found in several brain regions, including
the fimbria of the hippocampus, the reticular thalamic nucleus,
the corpus callosum, the external and internal capsule, the cin-
gulate cortex, and the anterior commissure nuclei (Figure 6F).602 Neuron 60, 598–609, November 26, 2008 ª2008 Elsevier Inc.These deposits were not fluorescent after thioflavine S staining,
indicating that they did not contain amyloid fibrils.
PrP deposition was associated with hypertrophy and prolifer-
ation of astrocytes, prominent in the hippocampus, amygdala,
and olfactory bulb as revealed by immunostaining with anti-glial
fibrillary acidic protein (GFAP) antibody (Figure S7). No spongi-
form-like changes were observed.
There is evidence that parvalbumin-, calbindin-, and calreti-
nin-positive subpopulations of GABAergic neurons are primarily
affected in CJD (Belichenko et al., 1999; Guentchev et al., 1997).
Immunohistochemistry for calretinin showed striking differences
in the hippocampus and cerebral cortex of Tg(CJD) mice
Neuron
Mouse Model of Inherited Creutzfeldt-Jakob Diseasecompared to controls (Figure 7; Figure S8). In non-Tg mice, the
anti-calretinin antibody strongly labeled bipolar neurons in layers
II and III of the cerebral cortex, mossy cells in the dentate gyrus of
the hippocampus, and their synaptic terminals projecting to the
supragranular zone. Tg(CJD) mice consistently showed mark-
edly less calretinin immunoreactivity of interneurons and neuropil
of the cerebral cortex and mossy cell terminals in the hippocam-
pus. The loss of calretinin immunoreactivity progressed with age
and correlated with the local deposition of PrP, although the two
proteins did not colocalize precisely (Figure S8). Synaptophysin
immunoreactivity was low in the supragranular layer of the hip-
pocampus where calretinin reduction was most pronounced
(data not shown).
These observations indicate a profound abnormality of calre-
tinin-positive fibers at the synaptic terminals up to their complete
disappearance.
Tg(CJD) Cerebellar Granule Neurons Show Swelling
of the ER and Abnormal Intracellular Localization of PrP
Histological analysis of Tg(CJD) brains did not find any obvious
signs of cerebellar degeneration, in contrast to other transgenic
mutant PrP models with similar motor dysfunctions (Chiesa et al.,
Figure 6. Tg(CJD) Mice Show Cerebral Accumulation of Protease-
Resistant PrP
(A and B) Immunohistochemical detection of PrP using monoclonal antibody
12B2 after PK digestion of a section in a 290-day-old Tg(CJD-A21+/+) mouse
(A) and a 396-day-old non-Tg/Prnp+/+ mouse (B).
(C and D) Immunohistochemical detection of PrP using monoclonal antibody
3F4 after PK digestion of a section in a 267-day-old Tg(CJD-A21+/+) mouse
(C) and a 293-day-old Tg(WT-E1+/) mouse (D).
(E and F) The pattern of PrP deposition in Tg(CJD) mice was either diffuse, as in
the hippocampal formation (E), or plaque-like, as in the anterior commissure
nucleus (F). Sections in (E) and (F) are from a 744-day-old Tg(CJD-A21+/)
mouse.
Scale bars = 1 mm in (A) (also applicable to [B]), 250 mm in (C) (also applicable to
[D]), and 25 mm in (E) and (F). Lmol, lacunosus molecular stratum; Mol, molec-
ular stratum; GrDG, granular zone of dentate gyrus.1998, 2000). Tg(CJD) cerebella were not atrophic judging from
morphometric measurements, nor did they show loss of granule
neurons or alterations of Purkinje cell density and dendritic ar-
borization in the molecular layer (Figure S9; data not shown).
Electron microscopy of Tg(CJD) cerebella, however, detected
striking ultrastructural abnormalities in granule neurons. The
ER of these cells was consistently enlarged and fragmented
(Figure 8A). These abnormalities were not seen in non-Tg/
Prnp0/0 or Tg(WT) mice, suggesting that they were related to
mutant PrP expression.
To test whether the ultrastructural alterations were associated
with accumulation of mutant PrP in the secretory pathway, we
used immunogold electron microscopy. Because immunostain-
ing of mutant PrP in brain sections requires antigen retrieval with
guanidine thiocyanate, which alters the tissue ultrastructure, we
made this analysis in primary cerebellar cultures established
from newborn mice. Preliminary tests showed that mutant PrP
could in fact be detected in paraformaldehyde/glutaraldehyde-
fixed neurons without the need for antigen retrieval. The majority
of wild-type PrP in granule neurons from non-Tg/Prnp+/+
and Tg(WT) mice localized on the plasma membrane and in
endosomes, with only a small fraction in the ER and the Golgi
Figure 7. Tg(CJD) Mice Show Low Calretinin Immunoreactivity in
Several Nerve Cell Populations
Sections from non-Tg/Prnp0/0 mice aged 245 (A and C), 334 (E), or 808 (G)
days; Tg(CJD-A21+/+) mice aged 284 (B and D) or 208 (F) days; and a 709-
day-old Tg(CJD-A21+/) mouse (H) were stained with anti-calretinin antibody.
In non-Tg mice, calretinin immunostaining labels bipolar and multipolar neu-
rons in layers II and III of the cerebral cortex (A and C) and the synaptic termi-
nals of the mossy cells in the supragranular zone of the dentate gyrus in the
hippocampus (E and G). Tg(CJD) mice show marked loss of calretinin immu-
noreactivity in cortical neurons (B and D) and hippocampal mossy cell termi-
nals (F and H). Scale bars = 250 mm in (A) and (E) (also applicable to [B] and
[F]), 15 mm in (C) (also applicable to [D]), and 50 mm in (G) (also applicable to [H]).Neuron 60, 598–609, November 26, 2008 ª2008 Elsevier Inc. 603
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Mouse Model of Inherited Creutzfeldt-Jakob Diseasecomplex (Figures 8Ba and 8C). In contrast, mutant PrP localized
mostly in the ER of Tg(CJD) neurons (75% versus 2.5% in
control cells), with a much smaller fraction of molecules on the
plasma membrane (15% versus 85% in controls) (Figures
8Bb, 8Bc, and 8C). Cultured cerebellar neurons from the mutant
mice showed striking alterations of the ER cisternae, which
appeared enlarged, swollen, and electron-dense (Figures 8Bb,
8Bc, and 8D).
These results indicate altered trafficking of mutant PrP to the
plasma membrane, protein retention in the ER, and morpholog-
ical abnormalities in intracellular organelles.
DISCUSSION
The D178N/V129 haplotype is linked to a CJD subtype that has
been described in families from Germany, France, Finland,
Israel, and America (Young et al., 1999). The disease is charac-
terized by early cognitive impairment with prominent memory
deterioration, abnormal behavior, and progressive signs of
motor dysfunction such as ataxia, tremor, and myoclonus, as
well as characteristic neuropathological signs. In the present
study, we found that mice carrying a transgene encoding
the mouse homolog of the CJD178 mutation accumulate an ab-
normal form of PrP in their brains and show neuropathological
Figure 8. Tg(CJD) Neurons Have Enlarged
Endoplasmic Reticulum and Abnormal In-
tracellular PrP Distribution
(A) Electron microscopy of granule neurons in the
cerebellumofa268-day-oldnon-Tg/Prnp0/0mouse
(Aa), a 262-day-old Tg(CJD-A21
+/
) mouse (Ab),
and a 43-day-old Tg(CJD-A21+/+) mouse (Ac). Ar-
rowheads point to the endoplasmic reticulum (ER)
cisternae, which are normal in the non-Tg control
(Aa) mouse but are fragmented and swollen in the
Tg(CJD) mice (Ab and Ac). Scale bar in (Ac) (appli-
cable to [Aa]–[Ac]) = 500 nm.
(B) Cultures of cerebellar granule neurons from
non-Tg/Prnp+/+, Tg(WT), and Tg(CJD-A21+/) mice
were fixed and labeled with anti-PrP antibody
using the Nanogold enhancement protocol. Wild-
type PrP is mostly found at the plasma membrane
(Ba); some staining is also visible in the ER (arrows)
and in the Golgi complex (arrowheads). D177N/
V128 PrP is mostly found in ER cisternae, which
appear moderately (Bb) or strongly (Bc) enlarged
and swollen. Scale bar in (Bc) (applicable to [Ba]–
[Bc]) = 250 nm.
(C) Quantification of gold particles in different cell
compartments. PM, plasma membrane.
(D) Quantification of ER and Golgi volumes of
cultured cerebellar granule neurons.
Data are the mean ± SD of at least 10 cells per
specimen.
changes of prion diseases. We also found
that the mutant mice develop a neurolog-
ical illness characterized by progressive
motor dysfunction, deficits in spatial
working memory, and abnormal sleep-
wake behavior with dramatic reduction
of REM sleep. Although sleep abnormalities are not commonly
considered symptoms of CJD178, we have now reported sleep
disorganization with severe reduction of REM epochs in a
recently diagnosed patient with the D178N/V129 mutation.
Thus, our combined behavioral and neurophysiological analyses
indicate that Tg(CJD) mice recapitulate essential clinical features
of CJD178. The results also suggest that perturbation of ER
homeostasis due to mutant PrP misfolding may be a critical
factor in neuronal dysfunction in inherited prion disease, indicat-
ing new pathogenic mechanisms and potential therapeutic
strategies.
Clinical Features of Tg(CJD) Mice
Tg(CJD) mice expressing mutant PrP at a level comparable to
that of endogenous PrP in wild-type mice develop a progressive
neurological disease that can be easily scored on the basis of ky-
phosis, foot clasp reflex, unbalanced body posture, and ataxia.
Tg(CJD) mice also show sensorimotor deficits, such as inability
to climb on a vertically oriented grill and poor performance on
a rotarod. These signs are indicative of motor dysfunction,
a prominent clinical feature of CJD. No neurological signs are ob-
served in nontransgenic littermates of Tg(CJD) mice or in Tg(WT)
mice, strongly indicating that the phenotype is due to expression
of the D177N/V128 transgene.604 Neuron 60, 598–609, November 26, 2008 ª2008 Elsevier Inc.
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nous level dramatically exacerbates the Tg(CJD) phenotype. Ho-
mozygous mice of the A21 line develop neurological signs much
earlier than hemizygous mice (at 145 versus 450 days of age)
and show much faster disease progression, reaching the termi-
nal stage in 130 days (Figure 2B). Moreover, the G5 founder,
which expressed eight times the endogenous PrP level, died
with neurological disease at only 72 days of age, further support-
ing a direct correlation between D177N/V128 level and disease
severity. In contrast, Tg(CJD) lines with PrP expression below
the endogenous level remain healthy during their lifetime. This
dose-dependent effect of mutant PrP expression has been de-
scribed in other PrP mutant mice (Chiesa et al., 2000; Nazor
et al., 2005; Telling et al., 1996) and supports the concept that
higher levels of mutant PrP molecules result in earlier onset
and a faster course of disease.
Consistent with the dominant mode of inheritance of CJD178
(Goldfarb et al., 1992), expression of wild-type PrP does not res-
cue the neurological illness of Tg(CJD) mice. Tg(CJD) mice car-
rying either one or two copies of the endogenous wild-type Prnp
allele develop neurological signs at an age similar to Tg(CJD)/
Prnp0/0 littermates and invariably progress to terminal disease.
Further experiments, however, are necessary to determine
whether coexpression of wild-type PrP modifies any other as-
pects of the Tg(CJD) phenotype, such as the deficits in working
memory or the alteration of sleep-wake patterns.
Memory loss is a distinctive early sign of CJD178 (Brown et al.,
1992). Tg(CJD) mice have a significant deficit in working memory
detectable in the eight-arm radial maze well before onset of neu-
rological signs. Tg(CJD) mice appear to be affected specifically
in this function since they have no significant alterations in
aspects of reference memory as measured by the passive avoid-
ance, object recognition, or Morris water maze tests. Interest-
ingly, Tg(CJD) mice show alterations in calretinin-positive mossy
cell terminals of the hippocampus and bipolar interneurons of the
cerebral cortex, which are thought to play important roles in spa-
tial orientation and working memory (Crusio and Schwegler,
2005; Wang et al., 2004).
EEGAbnormalities andSleepDisruption in Tg(CJD)Mice
and a CJD178 Patient
EEG alterations have been described in CJD since the early
1980s. The alterations depend on the stage of the disease, rang-
ing from nonspecific findings such as diffuse slowing and frontal
rhythmic delta activity in the early stage of disease to typical
PSWC in the middle and late stages. PSWC has been reported
in a carrier of the D178N/V128 mutation (Laplanche et al.,
1992) and were also detected in the patient analyzed here.
Tg(CJD) mice develop striking pathological EEG alterations
mimicking the human EEG pattern. Bursts of polyphasic com-
plexes and, to a lesser extent, ‘‘sawtooth’’ waves resemble the
EEG patterns observed in a feline model of CJD (Gourmelon
et al., 1987) and can be regarded as the equivalent of human
PSWC (Wieser et al., 2006).
Tg(CJD) mice also exhibit the sleep alterations seen in
sporadic CJD (Landolt et al., 2006) and in the CJD178 patient
described here. The most striking feature is a highly significant
reduction of REM sleep during both the light and dark phasesof the light-dark cycle in these mice. A second finding is the pres-
ence of epochs that cannot be assigned to any normal behav-
ioral state based on standard criteria used for the polygraphic
scoring of mouse sleep-wake behavior (‘‘unscored’’ epochs).
The pattern was similar in the CJD178 patient, who spent a signif-
icant amount of time in a condition that could not be assigned to
any normal vigilance or sleep state. A ‘‘nonwake-nonsleep’’ sub-
wakefulness state has been recognized in FFI (Montagna et al.,
2003) and in sporadic CJD (Landolt et al., 2006), and we found
a severe reduction of sleep efficiency, virtual absence of REM
sleep, and absence of usual ultradian modulation in our CJD178
patient.
Longitudinal 24 hr monitoring and spectral EEG analysis in FFI
patients show that an early and progressive reduction in thalamic
sleep spindles and K complexes is an early marker in the natural
history of the disease (Cortelli et al., 2006; Montagna et al., 2003);
spindling activity was completely absent in the whole 24 hr
recording of the CJD178 patient described here. Thus, sleep pro-
motion and organization appear to be altered in prion diseases
regardless of the specific etiology, suggesting a ‘‘continuum’’
between FFI, CJD178, and sporadic CJD.
The sleep-wake alterations observed in Tg(CJD) mice are not
seen in non-Tg littermates and Tg(WT) mice, consistent with
these alterations being caused by mutant PrP expression. PrP
may regulate circadian rhythm and promote sleep continuity
(Tobler et al., 1996), but no significant changes are seen in
the percentage of time spent in wakefulness, REM sleep, and
NREM sleep in Prnp0/0 mice. Therefore, the altered sleep-wake
behavior of Tg(CJD) mice seen here is unlikely to be due to
loss of any putative PrP function in sleep regulation.
Interleukin-1 and tumor necrosis factor are potent inhibitors of
REM sleep (Obal and Krueger, 2003). These cytokines are
elevated in sporadic and variant CJD and in CJD-infected mice
(Kordek et al., 1996; Sharief et al., 1999), suggesting their
involvement in the severe REM sleep reduction in Tg(CJD)
mice and the CJD178 patient.
Neuropathological Features and Biochemical
Properties of Mutant PrP in Tg(CJD) Mice
PrP deposition in most forms of prion disease is extracellular, oc-
curring either in typical amyloid plaques or as more diffuse ‘‘syn-
aptic-like’’ deposits in perineuronal and perivacuolar structures
throughout the neuropil. In familial CJD linked to the D178N/
V129 mutation, weak ‘‘synaptic-like’’ and small focal deposits
of PrP are observed (Parchi et al., 2003), and Tg(CJD) mice
have the same types of PrP deposits.
A striking pathological alteration in Tg(CJD) mice that appears
to be related to PrP deposition is the decrease of calretinin-pos-
itive GABAergic neurons in the dentate gyrus of the hippocam-
pus and in layers II and III of the neocortex. In the hippocampus,
loss of calretinin is accompanied by reduced synaptophysin
staining, suggesting that presynaptic terminals are affected. In
the neocortex, the decrease in calretinin is most evident in the
neuropil, whereas the cell bodies retain a certain degree of im-
munoreactivity. These observations suggest that nerve terminals
are primarily affected, consistent with the idea that synapses are
the main targets of abnormal PrP (Bouzamondo-Bernstein et al.,
2004; Jeffrey et al., 2000; Kitamoto et al., 1992).Neuron 60, 598–609, November 26, 2008 ª2008 Elsevier Inc. 605
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campus and cerebral cortex are selectively affected in sporadic
CJD and in experimental prion diseases (Guentchev et al., 1997,
1998). In sporadic CJD, parvalbumin-positive interneurons in the
frontal cortex are mostly involved, although there is also degen-
eration of calbindin- and calretinin-positive cells (Belichenko
et al., 1999).
In CJD-infected mice, loss of GABAergic inhibitory neurons oc-
curs very early after inoculation, suggesting that it may be an im-
portant step during disease development representing the basis
of excitatory symptoms (Guentchev et al., 1997, 1998). Whether
alterations of calretinin-positive GABAergic neurons in Tg(CJD)
mice contribute to the EEG abnormalities observed in this model
remains to be established.
Mutant PrP in the brains of Tg(CJD) mice can be distinguished
from PrPC by several biochemical properties, including propen-
sity to form detergent-insoluble aggregates, protease resistance,
and reactivity with the 15B3 antibody. D177N/V128 PrP, however,
differs from mutant PrP in the brains of CJD178 patients because it
is much less protease resistant and has a smaller protease-resis-
tant core, suggesting possible structural differences. Experi-
ments to test whether mutant PrP in Tg(CJD) brains is infectious
like that in CJD178 patients (Brown et al., 1992) are underway.
Impaired Trafficking ofMutant PrP and Its Potential Role
in Disease Pathogenesis
We observed that the ER of Tg(CJD) cerebellar granule neurons
was dramatically swollen and electron-dense and contained
abnormal amounts of mutant PrP. These data suggest that ER
retention of mutant PrP may be an instigating pathogenic mech-
anism in cerebellar granule neurons that could also be active in
other neuronal populations.
A number of inherited human diseases are attributable to
defects in export of a mutant protein out of the ER (Aridor and
Hannan, 2002). In some cases the misfolded mutant protein is tri-
aged by the ER quality control and degraded by the proteasome;
in other cases it is retained in the ER lumen and stimulates ER
stress response pathways, such as the unfolded protein re-
sponse (UPR), eventually leading to apoptosis (Kaufman,
1999). We have reported that PrP molecules carrying the
D177N mutation are delayed in their biosynthetic maturation in
the ER (Drisaldi et al., 2003) but are not subject to retrotransloca-
tion and proteasomal degradation in cerebellar granule neurons
(Fioriti et al., 2005). No signs of UPR were detected in the brains
of carriers of the D178N/V129 mutation (Unterberger et al.,
2006), and we did not find splicing of the mRNA encoding X
box-binding protein 1 or increased expression of UPR-regulated
genes such as Grp78/Bip and CHOP/GADD153 in the brains of
Tg(CJD) mice (data not shown), suggesting that some other
pathogenic mechanism may be triggered by this mutation. ER
overload with mutant PrP may lead to activation of NF-kB
(Pahl and Baeuerle, 1997), with possible consequences for neu-
ronal function and synaptic plasticity (O’Mahony et al., 2006). Al-
ternatively, buildup of the mutant protein in the ER may perturb
the ER calcium signaling essential for normal neuronal function
(Mattson et al., 2000). Finally, aggregation of mutant PrP in the
secretory pathway may interfere with folding, assembly, and
transport of other membrane proteins, such as multimeric ion606 Neuron 60, 598–609, November 26, 2008 ª2008 Elsevier Inc.channels or receptors (Schwappach, 2008), leading to defective
synaptic transmission.
The fact that Tg(CJD) mice accumulate a misfolded form of
mutant PrP in their brains and develop clinical features of CJD ar-
gues that essential aspects of pathogenesis are modeled in
these animals. Tg(CJD) mice may be suitable for investigating
disease mechanisms and testing potential therapies in inherited
prion diseases. Since the mutant mice spontaneously develop
profound alterations of sleep-wake behavior, they offer a unique
model for investigating the pathophysiology of sleep in prion dis-
orders. Finally, comparative studies of Tg(CJD) and transgenic
mice expressing other mutant PrPs may provide important infor-
mation on the cellular and molecular mechanisms responsible
for the phenotypic heterogeneity of inherited prion diseases.
EXPERIMENTAL PROCEDURES
Generation of Transgenic Mice
Production of transgenic Tg(WT) mice expressing wild-type PrP tagged with an
epitope for the monoclonal antibody 3F4 has been reported previously (Chiesa
et al., 1998). In this study, we used hemizygous or homozygous mice of the E1
line, which express two and four times the endogenous PrP level, respectively.
The cDNA encoding mouse PrP derived from the Prnpa allele and containing
the 3F4 epitope tag and the D177N and M128V substitutions has been de-
scribed previously (Fioriti et al., 2005). The coding region of this cDNA was am-
plified by PCR using Vent polymerase (New England Biolabs) and ligated into
the MoPrP.Xho vector, which contains a 12 kb fragment of Prnp, including the
promoter and intron 1, and drives expression of transgenic PrP in a tissue pat-
tern similar to that of the endogenous protein (Borchelt et al., 1996). Recombi-
nant plasmids were selected by PCR screening and restriction analysis, and
their identity was confirmed by sequencing the entire coding region (Chiesa
et al., 1998). The transgene was excised by NotI digestion and injected into
the pronuclei of fertilized eggs from an F2 cross of C57BL/6J3 CBA/J F1 pa-
rental mice. Transgenic founders were bred with an inbred colony of Zu¨rich I
Prnp0/0 mice (C57BL/6J 3 129 background) (Bueler et al., 1992; Chiesa
et al., 2000). The status of the Prnp gene and the presence of the transgene
were determined by PCR, and the zygosity of the transgene was determined
by Southern blot analysis (Chiesa et al., 1998). The transgenic lines were
maintained on the Prnp0/0 genotype. For some experiments, the Prnp allele
was reintroduced by breeding transgenic mice to C57BL/6J 3 CBA/J mice;
nontransgenic Prnp+/+ and Prnp0/0 littermates were used as controls.
All procedures involving animals and their care were conducted according
to European Union (EEC Council Directive 86/609, OJ L 358,1; December
12, 1987) and Italian (D.L. n.116, G.U., suppl. 40; February 18, 1992) laws
and policies and in accordance with the United States Department of Agricul-
ture Animal Welfare Act and National Institutes of Health Policy on Humane
Care and Use of Laboratory Animals.
Biochemical Analyses
Tissue homogenates were prepared in phosphate-buffered saline (PBS) con-
taining 0.5% NP-40 and 0.5% sodium deoxycholate using a glass/Teflon tis-
sue homogenizer. In some experiments, protease inhibitor cocktail (1 mg/ml
pepstatin and leupeptin; 0.5 mM phenylmethylsulfonyl fluoride; 2 mM EDTA)
was added to the homogenization buffer. Assays of detergent insolubility, pro-
teinase K (PK) resistance, and immunoprecipitation with antibody 15B3 were
carried out as described previously (Biasini et al., 2008; Chiesa et al., 1998;
Tremblay et al., 2004). Western blots were developed with monoclonal anti-
body 3F4 (Kascsak et al., 1987), which selectively recognizes transgenic
PrP, or polyclonal antibody P45–66 raised against a synthetic peptide encom-
passing residues 45–66 of mouse PrP.
Clinical Analysis of Mice
Mice were observed weekly for signs of neurological dysfunction according to
a set of objective criteria (Chiesa et al., 1998). Onset of disease was scored as
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served: foot-clasp reflex, kyphosis, unbalanced body posture, inability to
walk on a horizontal metal grid, and inability to remain on a vertical grid for
at least 30 s. An accelerating Rota-Rod 7650 (Ugo Basile) was used; mice
were first trained twice the week before official testing. They were positioned
on the rotating bar and allowed to become acquainted with the environment for
30 s. The rod motor was started at an initial setting of 3 rpm and accelerated to
30 rpm at a constant rate of 0.3 rpm/s for a maximum of 300 s. The perfor-
mance was scored as latency to fall, in seconds. Animals were given three tri-
als, and the average was used for statistical analysis.
Radial Maze
Spatial working memory was measured using an eight-arm radial maze made
of gray plastic with a Plexiglas lid. The arms, which radiated from an octagonal
central arena with a diameter of 12 cm, were 30 cm long, 5 cm wide, and 4 cm
high. Several external visual cues surrounded the apparatus. Starting one
week before testing, the mice were water deprived by being given access to
water for only 1 hr per day. One day before starting the task schedule, a habit-
uation trial was run. The mice were placed in the center of the maze and let free
to explore the environment for 10 min. The next day, the arms of the radial
maze were baited with 50 ml of water. Animals were placed in the center of
the maze, and the arm entry sequence was recorded. The task ended once
all eight arms of the maze had been visited or after a maximum of 16 trials,
whichever came first. Repeated entry into an arm that had already been visited
constituted an error. The number of errors and the latency to complete the test
were recorded manually by an operator (A.G.) blinded to the experimental
groups. Animals were tested for 10 consecutive days.
EEG and Sleep-Wake Behavior
EEG and sleep patterns were investigated in six non-Tg/Prnp+/+, six non-Tg/
Prnp0/0, sixTg(CJD-A21+/), and five Tg(WT-E1+/+)mice.Micewere anesthetized
and instrumented for chronic EEG recording according to standard techniques
(Baracchi and Opp, 2008) and then allowed at least 10 days to recover from sur-
gery and adapt to the recording conditions. Mice were individually housed in
standard cages with food and water ad libitum. Cages were kept in sound-atten-
uated boxes at a constant temperature between 24.5C and 26.0C, with a 12/
12 hr light-dark cycle. Gross body activity was detected using an infrared sensor
housed in an observation unit that also contained a camera (BIOBSERVE GmbH)
allowing continuous recording of the animals’ behavior. Movements detected by
the infrared sensor were converted to a voltage output. The conditioned EEG
signal and the voltage output from the infrared sensor were digitized and col-
lected using custom software (M.R. Opp, University of Michigan). EEG signals
and gross body activity were recorded for 24 hr (starting at first light) in undis-
turbed conditions and used for polygraphic determination of vigilance state.
The animals were not handled starting from 48 hr before the recording session.
Two mice of different genotypes were randomly matched and recorded simulta-
neously.The orderof recording ofmiceof the different lines was also randomized.
Postacquisition determination of vigilance state was performed according to
standard criteria (Baracchi and Opp, 2008). Visual scoring of 12 s epochs was
performed by an investigator (L. Ferrari or S.B.) blinded to the strain. As de-
scribed in Results, it was sometimes impossible to assign certain epochs to
any behavioral state in Tg(CJD) mice. In these cases, epochs were classified
as ‘‘unscored.’’ EEG power density values were obtained for each animal
and each behavioral state by Fourier transform for each artifact-free 12 s scor-
ing epoch for the frequency range 0.5–20 Hz.
Histology
Brains were fixed in Carnoy’s fixative (6:3:1 ethanol:chloroform:acetic acid),
dehydrated in graded ethanol solutions, cleared in xylene, and embedded in
paraffin. Serial sections (5 mm thick) were cut and stained with hematoxylin
and eosin, Nissl, or thioflavin S. Some sections were immunostained with
rabbit polyclonal anti-glial fibrillary acidic protein (GFAP) (Dako, 1:1000),
anti-calretinin (Swant, 1:2000), anti-calbindin (Chemicon, 1:1000), or anti-
synaptophysin (Dako, 1:200), followed by visualization with a Vectastain
ABC kit (Vector) using 3,30-diaminobenzidine as chromogen. Alexa 488- or
Alexa 546-conjugated secondary antibodies (Molecular Probes Inc.) were
used for immunofluorescence.For PrP immunohistochemistry, sections were incubated with PK (2 mg/ml in
0.1% Brij-35, 50 mM NaCl, 50 mM Tris-HCl [pH 7.8]) for 30 min at room tem-
perature and exposed to guanidine thiocyanate (3 M in H2O) for 30 min (Giac-
cone et al., 2000). PK-resistant PrP was detected with monoclonal antibody
3F4 (1:200) (Kascsak et al., 1987) or 12B2 (1:1000) (Langeveld et al., 2006).
Results were similar with the two antibodies.
Electron Microscopy
One 269-day-old Tg(WT) mouse, two non-Tg/Prnp0/0 mice aged 268 and
392 days, two Tg(CJD-A21+/)/Prnp0/0 mice aged 262 and 488 days, and
one 43-day-old Tg(CJD-A21+/+)/Prnp0/0 mouse were deeply anesthetized
and perfused through the ascending aorta with PBS (0.1 M; pH 7.4) followed
by 4% paraformaldehyde (PFA) and 2.5% glutaraldehyde in PBS. The cerebel-
lum was excised and cut along the sagittal plane with a razor blade, postfixed
in 3% glutaraldehyde in PBS, and immersed for 2 hr in OsO4. After dehydration
in a graded series of ethanol, tissue samples were cleared in propylene oxide,
embedded in Epon 812 epoxy medium (Fluka), and polymerized at 60C for
72 hr. From each sample, one semithin section (1 mm) was cut with a Leica
EM UC6 ultramicrotome and mounted on glass slides for light microscopic
inspection to identify the Purkinje and granular cell layers. Ultrathin sections
(70 nm thick) of the area of interest were obtained, counterstained with uranyl
acetate and lead citrate, and examined with an energy filter transmission elec-
tron microscope (Zeiss LIBRA 120 EFTEM) equipped with a YAG scintillator
slow-scan CCD camera.
Immunoelectron Microscopy
Cerebellar granule neurons were prepared from 6-day-old mice as described
previously (Fioriti et al., 2005) and cultured for 7 days before immunoelectron
microscopy. Cells grown on poly-L-lysine-coated glass coverslips were
washed with PBS and fixed in a solution of 4% PFA and 0.1% glutaraldehyde
in 0.2 M HEPES buffer (pH 7.4) for 15 min at room temperature. After washing
with PBS, cells were incubated for 30 min in blocking solution (50 mM NH4Cl,
0.1% saponin, 1% BSA in HEPES buffer) and then overnight at 4C with anti-
PrP monoclonal antibody SA65 (Matucci et al., 2005) or 12B2 (Langeveld et al.,
2006) diluted 1:250 in blocking solution. Cells were washed and incubated for
1 hr at room temperature with Nanogold-conjugated anti-mouse IgG Fab0 frag-
ment diluted 1:100 in blocking solution and processed according to the Nano-
gold enhancement protocol (Nanoprobes). Stained cells were embedded in
Epon 812 and cut as described previously (Polishchuk et al., 2003). EM images
were acquired from thin sections using a Philips Tecnai 12 electron micro-
scope equipped with an ULTRA VIEW CCD digital camera (Philips). Gold par-
ticles were quantified in the different compartments of the secretory pathway,
and total cell, ER, and Golgi volumes were analyzed using analySIS software
(Soft Imaging Systems GmbH). The SA65 and 12B2 antibodies yielded similar
results.
Polysomnography
The 24 hr EEG recordings, including complete polysomnography, were taken
according to guidelines approved by the Standards of Practice Committee of
the American Academy of Sleep Medicine (Kushida et al., 2005). The EEG was
acquired with Ag/AgCl electrodes positioned over the vertex and the frontal,
central, and occipital regions bilaterally, according to the International 10-20
Electrode Placement System. Two electrooculographic channels, respiratory
channels, electrocardiography, bilateral tibialis anterior, and chin electromy-
ography were also recorded. All signals were digitalized at a sampling rate
of 256 Hz. The record was visually scored according to standard criteria (Re-
chtschaffen and Kales, 1968), and the hypnogram was stored digitally, linked
to the recording. Arousals, cardiorespiratory events, and EMG activities were
recognized by dedicated software and reviewed by a clinical neurophysiolo-
gist trained in sleep medicine. A control 24 hr recording was taken in an
age-matched healthy subject in the same sleep laboratory.
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